Records containing: Progressive Multiple Sclerosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-27Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics
-
CLINICAL_TRIALS study record update · 2026-04-23A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2026-03-23A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2026-03-12Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2026-02-12Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-01-23Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2025-12-31A Phase I Study of Circadian Focused Light Therapy for Fatigue Reduction in Progressive Multiple Sclerosis (NO-FATIGUE)
-
CLINICAL_TRIALS study record update · 2025-11-20An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
-
CLINICAL_TRIALS study record update · 2025-10-31RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2025-09-30Serum Neurofilaments Light Chain and GFAP (Glial Fibrillary Acidic Protein) in Atypical Idiopathic Inflammatory Demyelinating Disorders
-
CLINICAL_TRIALS study record update · 2025-09-12A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
-
CLINICAL_TRIALS study record update · 2025-09-08ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?
-
CLINICAL_TRIALS study record update · 2025-07-03A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2025-05-16Visual Processing Speed and Objective Analysis of Supranuclear Ocular Movements Control in Multiple Sclerosis Patients and Its Relationship With OCT and Reading Difficulties
-
CLINICAL_TRIALS study record update · 2025-04-04Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics
-
CLINICAL_TRIALS study record update · 2025-02-27Understanding the Effect of Variances on Precision in Predictive Coding When Walking to Music and Metronomes in Persons With Multiple Sclerosis With Progressive Subtypes.
-
CLINICAL_TRIALS study record update · 2024-10-16Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2024-07-03The Effectiveness of Combining a Home-based Digital Motor Telerehabilitation Program With Conventional Therapy in Progressive Multiple Sclerosis: a Multicentre, Randomized Controlled Trial
-
CLINICAL_TRIALS study record update · 2024-01-11Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study
-
CLINICAL_TRIALS study record update · 2024-01-08Multiple Sclerosis Prediction and Monitoring of Progression Study
-
CLINICAL_TRIALS study record update · 2023-07-10Exploratory Trial of Forza™️, a Novel Nutraceutical From Actinidia Deliciosa Plants Bioengineered to Bio-encapsulate the Osmotin Plant Protein as Adjuvant for the Treatment of Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-05-03A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients
-
CLINICAL_TRIALS study record update · 2022-05-12An Open-label, Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668
-
CLINICAL_TRIALS study record update · 2022-04-25A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2022-02-14G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis